Literature DB >> 12143224

An anti-apoptosis gene, survivin and telomerase expression in gastric cancer.

Akira Tsuburaya1, Yoshikazu Noguchi, Takaki Yoshikawa, Aya Saito, Chiharu Doi, Takahide Okamoto, Kuniyasu Fukuzawa.   

Abstract

BACKGROUND/AIMS: Survivin is frequently expressed in various malignancies as an inhibitor of programmed cell death, while telomerase is associated with cell immortality and consequent accumulation of a malignant genetic property. We surmised that an activation of telomerase in combination with an inhibition of apoptosis might further accelerate growth of malignant tumors. To test this hypothesis, we investigated the expression of survivin and telomerase in stomach cancer.
METHODOLOGY: Twenty-five consecutive patients who underwent gastrectomy for stomach cancer were studied including 13 patients at stage 4, 7 of whom had peritoneal metastasis. The expression of survivin and telomerase in the tumors were studied by a reverse transcriptase-polymerase chain reaction.
RESULTS: Survivin mRNA was detected in 16 (64%) out of 25 tumors and telomerase mRNA in 24 (96%) of them. Survivin expression was inversely associated with the depth of tumor and peritoneal metastasis, while histology, lymph node metastasis, stage, and telomerase expression were not associated. DNA fragmentation was observed in 8 out of 15 tumors including 4 of 9 survivin positive tumors and 4 of 6 survivin negative tumors (n.s.).
CONCLUSIONS: Survivin was not likely to be related with an inhibition of apoptosis or induction of telomerase but may have some role in gastric cancer extension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12143224

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis.

Authors:  Andreas Krieg; Billur Baseras; Monika Tomczak; Pablo Emilio Verde; Nikolas Hendrik Stoecklein; Wolfram Trudo Knoefel
Journal:  Mol Biol Rep       Date:  2013-08-15       Impact factor: 2.316

2.  Downregulation of survivin inhibits proliferation and migration of human gastric carcinoma cells.

Authors:  Yandong Li; Yongli Zhou; Jianyun Zheng; Chunyan Niu; Bing Liu; Meini Wang; Hangrong Fang; Chuan Hou
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Reg IV enhances peritoneal metastasis in gastric carcinomas.

Authors:  H Kuniyasu; N Oue; T Sasahira; L Yi; Y Moriwaka; T Shimomoto; K Fujii; H Ohmori; W Yasui
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

4.  Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

Authors:  Jie Wang; Ze Lu; Bertrand Z Yeung; M Guillaume Wientjes; David J Cole; Jessie L-S Au
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

5.  Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer.

Authors:  Hao Deng; Ren-Liang Wu; Hong-Yan Zhou; Xuan Huang; Ying Chen; Li-Jiang Liu
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

Review 6.  Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer.

Authors:  Ting-Ting Wang; Xiao-Ping Qian; Bao-Rui Liu
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

7.  Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas.

Authors:  Levent Dizdar; Monika Tomczak; Thomas A Werner; Sami A Safi; Jasmin C Riemer; Pablo E Verde; Nikolas H Stoecklein; Wolfram T Knoefel; Andreas Krieg
Journal:  Oncol Lett       Date:  2017-09-19       Impact factor: 2.967

8.  Dual targeting of survivin and X-linked inhibitor of apoptosis protein suppresses the growth and promotes the apoptosis of gastric cancer HGC-27 cells.

Authors:  Yanfeng Li; Wenbo Gao; Yan Ma; Guanyu Zhu; Fuhui Chen; Hongyan Qu
Journal:  Oncol Lett       Date:  2018-07-05       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.